Search hospitals > Utah > Salt Lake City
Huntsman Cancer Institute/University of Utah
Claim this profileSalt Lake City, Utah 84112
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Leukemia
Conducts research for Tumors
Conducts research for Melanoma
1129 reported clinical trials
82 medical researchers
Summary
Huntsman Cancer Institute/University of Utah is a medical facility located in Salt Lake City, Utah. This center is recognized for care of Cancer, Breast Cancer, Leukemia, Tumors, Melanoma and other specialties. Huntsman Cancer Institute/University of Utah is involved with conducting 1,129 clinical trials across 797 conditions. There are 82 research doctors associated with this hospital, such as Heloisa Soares, Michael Pulsipher, MD, Theresa Werner, MD, and Sunil Sharma.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderStage IV
HER2 negative
HER2 positive
Top PIs
Heloisa SoaresHuntsman Cancer Institute/University of Utah2 years of reported clinical research
Expert in Neuroendocrine Tumors
Studies Colorectal Cancer
25 reported clinical trials
50 drugs studied
Michael Pulsipher, MDChildren's Hospital Los Angeles5 years of reported clinical research
Studies Leukemia
Studies Lymphoblastic Leukemia-Lymphoma
16 reported clinical trials
31 drugs studied
Theresa Werner, MDHuntsman Cancer Institute/University of Utah2 years of reported clinical research
Studies Ovarian Cancer
Studies Adenocarcinoma
11 reported clinical trials
20 drugs studied
Sunil SharmaHonorHealth Research Institute4 years of reported clinical research
Studies Tumors
Studies Cancer
16 reported clinical trials
34 drugs studied
Clinical Trials running at Huntsman Cancer Institute/University of Utah
Esophageal Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Esophageal Carcinoma
Prostate Cancer
Breast Cancer
Diffuse Large B-Cell Lymphoma
Cancer
Lymphoma
Bladder Cancer
Esophageal Cancer
Chemotherapy + Radiotherapy
for Esophageal and Gastric Cancer
This phase III trial studies how well the addition of radiotherapy to the usual treatment (chemotherapy) works compared to the usual treatment alone in treating patients with esophageal and gastric cancer that has spread to a limited number of other places in the body (oligometastatic disease). Radiotherapy uses high energy x-rays, gamma rays, or protons to kill tumor cells and shrink tumors. Drugs used in usual chemotherapy, such as leucovorin, 5-fluorouracil, oxaliplatin, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding radiotherapy to the usual chemotherapy may work better compared to the usual chemotherapy alone in treating patients with esophageal and gastric cancer.
Recruiting2 awards Phase 320 criteria
Chemotherapy + Immunotherapy
for Esophageal and Gastric Cancer
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
Recruiting2 awards Phase 32 criteria
Proton Therapy vs Photon Radiation
for Esophageal Cancer
This trial studies how well proton beam radiation therapy compared with intensity modulated photon radiotherapy works in treating patients with stage I-IVA esophageal cancer. Proton beam radiation therapy uses a beam of protons (rather than x-rays) to send radiation inside the body to the tumor without damaging much of the healthy tissue around it. Intensity modulated photon radiotherapy uses high-energy x-rays to deliver radiation directly to the tumor without damaging much of the healthy tissue around it. It is not yet known whether proton beam therapy or intensity modulated photon radiotherapy will work better in treating patients with esophageal cancer.
Recruiting2 awards Phase 31 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Huntsman Cancer Institute/University of Utah?
Huntsman Cancer Institute/University of Utah is a medical facility located in Salt Lake City, Utah. This center is recognized for care of Cancer, Breast Cancer, Leukemia, Tumors, Melanoma and other specialties. Huntsman Cancer Institute/University of Utah is involved with conducting 1,129 clinical trials across 797 conditions. There are 82 research doctors associated with this hospital, such as Heloisa Soares, Michael Pulsipher, MD, Theresa Werner, MD, and Sunil Sharma.
Where is Huntsman Cancer Institute/University of Utah located?
The Huntsman Cancer Institute/University of Utah Hospital is situated at 1950 Circle of Hope Dr, Salt Lake City, UT 84112, on the University of Utah campus's northeast corner, adjacent to Primary Children’s Hospital and University of Utah Hospital. Complimentary valet parking is provided Monday through Friday, from 7:00 am to 5:30 pm.
Who should I call to ask about financial aid or insurance network?
For financial assistance and insurance-related inquiries at Huntsman Cancer Institute/University of Utah hospital, contact the Billing Office at 801-587-6303 or 800-862-4937. For assistance with your bill, reach out to a financial advocate at 801-581-2957. For online billing consultations, schedule an appointment or call 801-587-6303.
What insurance does Huntsman Cancer Institute/University of Utah accept?
The Huntsman Cancer Institute/University of Utah accepts a wide range of insurance plans, such as SelectHealth Medicare Advantage, Aetna, American Health Plans, Blue Cross Blue Shield, and Cigna. SelectHealth Medicare Advantage members benefit from access to the Huntsman Cancer Institute through the SelectHealth Medicare Advantage Network Expansion. Additionally, the University of Utah Health collaborates with most major health insurance carriers and transplant networks.
What awards or recognition has Huntsman Cancer Institute/University of Utah received?
Huntsman Cancer Institute at the University of Utah is recognized as the only National Cancer Institute-designated Comprehensive Cancer Center in the Mountain West, serving a broad region. It boasts a distinguished history of cancer genetics research, leveraging the Utah Population Database, the largest of its kind in the U.S., to identify genetic patterns of cancer in families. The institute leads in discovering genes for inherited cancers and operates the most extensive Phase 1 clinical cancer research program in the Mountain West, offering around 325 clinical trials.